SecBot SecBot

ESLAW

Estrella Immunopharma, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001844417 Biotech & Drug Discovery
Warrants of Estrella Immunopharma, Inc. · ESLA stock page →
—
Market cap
$3.0M
Nano cap
1 year
−59.7%
from $2.28 · Oct 27
30 days
+113.2%
from $0.4310
52-week range
$0.3140–3.05
−70% from high · low Oct 13
Avg volume 20D
5.55M
Oct 15 spike 63.11M
Short interest
🔒 Subscribers only
New fund stakes
0
Q4 2025 13F · 0 exits
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL Estrella Immunopharma filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q4 2025: 0 added (0 new), 1 trimmed or exited.

  • TrendUPTREND

    58% above its 50-day average.

Who's buying

13F· Q4 2025
0
new positions
0
exits
FundMoveSharesValue
TORONTO DOMINION BANKTRIM21,635$1.1K
UBS Group AGTRIM1,332$47.00
Walleye Trading LLCDOUBLED92,970$8.2K
Walleye Capital LLCNEAR_EXIT10,330$908.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 9, 2026 Listing status
Listing Status: ESLAW — Deficient (was Normal)
Estrella Immunopharma, Inc. - Warrant | Nasdaq Financial Status Indicator N → D
Apr 30, 2026 SEC
Estrella Immunopharma filed Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors…
10-K/A — Impact 2/10
Dec 31, 2025 Inst.
TORONTO DOMINION BANK — TRIM
21,635 shares ($1.1K)
Jun 30, 2025 Inst.
UBS Group AG — TRIM
1,332 shares ($47.00)

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 9, 2026
Listing
Listing Status: ESLAW — Deficient (was Normal)
Estrella Immunopharma, Inc. - Warrant | Nasdaq Financial Status Indicator N → D
Jul 6, 2026
Listing
Listing Status: ESLAW — Normal (was Deficient)
Estrella Immunopharma, Inc. - Warrant | Nasdaq Financial Status Indicator D → N

SecBot reports

1 filing · 0 bullish · 0 bearish · 1 neutral
All ESLAW filing & press-release reports (1)